The present invention relates to a novel serotonin reuptake inhibitor having 5-HT2C antagonism, particularly, also having 5-HT2C inverse agonism, which contains a compound represented by formula (1) or a pharmaceutically acceptable salt thereof and has antidepressive activity and anxiolytic activity. In formula (1), R1, R2, R3, and R4 each independently represent a hydrogen atom, a C1-6 alkyl group, or the like； R5 represents a C4-7 alkyl group or -(CR8R9)r-E； R6, R7, R8, and R9 each independently represent a hydrogen atom, a fluorine atom, or a C1-6 alkyl group； A represents a C6-10 aryl group, a heteroaryl group, or the like； r represents 1, 2, 3, or 4； E represents a C3-8 cycloalkyl group, a C6-10 aryl group, or the like； L represents an oxygen atom, a sulfur atom, or -NR10-； n represents 1, 2, or 3； R10 represents a hydrogen atom, a C1-6 alkyl group, or the like； and X represents a hydrogen atom, a halogen atom, or the like.
